Fast dissolving pharmaceutical composition
AssigneeFerring B.V.
InventorsShweta Gupta, Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
Life of this patent
Estimating the term…
Abstract
The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.
Claims23
A pharmaceutical composition comprising:
- (a) at least one matrix-forming agent that is levan to form an open matrix network;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin and desmopressin acetate carried by the open matrix network,
- wherein at least 80% of the composition dissolves within 30 seconds upon contact with an aqueous solution or with saliva, and the composition is an orodispersible pharmaceutical dosage form.
A pharmaceutical composition prepared by a process comprising at least a step of sublimating a solvent from a liquid preparation that comprises:
- (a) at least one matrix forming agent that is levan;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin and desmopressin acetate,
- wherein at least 80% of the composition dissolves within 30 seconds upon contact with an aqueous solution or with saliva, and the composition is an orodispersible pharmaceutical dosage form.
A pharmaceutical composition comprising:
- (a) at least one matrix-forming agent that is levan to form an open matrix network;
- and
- (b) desmopressin carried by the open matrix network,
- wherein at least 80% of the composition dissolves within 30 seconds upon contact with an aqueous solution or with salvia, and the composition is an ordodispersible pharmaceutical dosage form.
A blister pack having one or more depressions disposed therein, wherein each of the one or more depressions comprises a pharmaceutical composition, the composition comprising:
- (a) at least one matrix-forming agent that is levan to form an open matrix network;
- and
- (b) at least one pharmaceutically active ingredient chosen from desmopressin and desmopressin acetate carried by the open matrix network,
- wherein at least 80% of the tablet dissolves within 30 seconds upon contact with an aqueous solution or with saliva, and the composition is an orodispersible pharmaceutical dosage form.
Dependencies are inferred from the claim text.